<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694820</url>
  </required_header>
  <id_info>
    <org_study_id>20P.140</org_study_id>
    <nct_id>NCT04694820</nct_id>
  </id_info>
  <brief_title>A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia</brief_title>
  <official_title>txt4TKI: An Innovative Mobile Intervention to Improve Tyrosine Kinase Inhibitor Management Among Chronic Myeloid Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI&#xD;
      for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid&#xD;
      leukemia. Tyrosine kinase inhibitors (TKI) are associated with numerous potential side&#xD;
      effects, including a decrease in bone marrow activity (myelosuppression), nausea, diarrhea,&#xD;
      fatigue, and soft-tissue swelling (edema), especially in the face and lower legs, which are&#xD;
      the primary reasons for patients to discontinue TKI medication. Using a mobile text messaging&#xD;
      (TXT) intervention that emphasizes the importance of TKI compliance may improve TKI adherence&#xD;
      in patients with chronic myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of TKI Treatment Date</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be extracted from the electronic medical record (EMR) chart, including tyrosine kinase inhibitor (TKI) treatment initiation dates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of TKI Treatment change</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be extracted from the electronic medical record (EMR) chart, including change of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of TKI Discontinuation</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be extracted from the electronic medical record (EMR) chart, including discontinuing treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Compliance</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured through study accrual, attrition, adverse event monitoring data, and system usage frequencies. 90% of the study participants adequately use the smart pill bottles will be acceptable. The intervention will be considered feasible if attrition does not exceed 30%. 90% of participant texting back to the system at least once will be considered adequate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Mobile Involvement</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured through a satisfaction measure and patient interview data. Acceptability will be established by a group median score &gt;= 3 on the 1-4 satisfaction scale. Further, transcripts of the audio recorded post-intervention patient interviews will be analyzed using grounded theory and constant comparative methods. Analysis will examine patient perceptions of the usefulness and satisfaction with the txt4TKI intervention. After the research team reaches a consensus on a coding scheme, the principal investigator (PI) and the project manager will code independently the transcripts, examining patient's satisfaction with and evaluation of the txt4TKI intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI adherence</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be assessed by AdhereTech wireless smart pill bottes for all participants, which are Health Insurance Portability and Accountability Act (HIPAA)-compliant Food and Drug Administration (FDA) class I medical devices that monitor electronic tracking of bottle and percent of pills detected inside the bottle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom burden</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>The MD Anderson Symptom Inventory-Chronic Myeloid Leukemia (MDASI-CML) will be used to assess patient symptom burden.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knowledge and self-efficacy for taking medication</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured by the Medication Understanding and Use Self-Efficacy (MUSE) Scale. It measures patients' self-efficacy in understanding and using medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barriers to adherence and problems with adherence behavior</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be assessed by the Adherence Starts With Knowledge 12 Questionnaire (ASK-12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beliefs in medications</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured using the Beliefs in Medicines Questionnaire (BMQ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual illness perceptions</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be assessed using Brief-Illness Perceptions Questionnaire (B-IPQ) that includes survey items assessing individual illness perceptions along the cognitive domains of the self-regulatory model as well as emotional responses to having CML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-efficacy for medication use</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured using the 13-item Self-efficacy for Appropriate Medication Use Scale (SEAMS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be assessed using the Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Questionnaire consisting of leukemia-specific sub scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be assessed using the Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Questionnaire consisting of a set of general HRQoL questions (Functional Assessment of Cancer Therapy-General [FACT-G])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-efficacy for managing symptoms</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured by a modified version of Lorig's Chronic Disease Self-Efficacy Scale for managing symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Affect</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>The Intrusion subscale of the Revised Impact of Events Scale (RIES) will be used to assess affective distress concerning TKI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social Support</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Will be measured using the Multidimensional Scale of Perceived Social Support (MSPSS). The MSPSS assesses perceptions of support received from family, friends, and significant others.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Usefulness and satisfaction of txt4TKI</measure>
    <time_frame>Up to 6 months post-baseline</time_frame>
    <description>Patient interviews will explore key domains including perceived usefulness, how well txt4TKI address their concerns, whether there are additional issues they would like to see included and the characteristics of the text messaging (TXT). Client Satisfaction Questionnaire (CSQ-8) structured measures will ask participants to rate the usefulness and satisfaction of txt4TKI and how likely they would recommend the program to others.</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Text Message-Based Navigation Intervention</intervention_name>
    <description>Receive txt4TKI</description>
    <other_name>Automated Text Message-Based Navigation, Text Message-Based Navigation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PHASE 1: Patients diagnosed with chronic myeloid leukemia&#xD;
&#xD;
          -  PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year&#xD;
&#xD;
          -  PHASE 1: Able to read and understand English&#xD;
&#xD;
          -  PHASE 1: Able to provide informed consent&#xD;
&#xD;
          -  PHASE 1: Have a mobile phone with TXT capability&#xD;
&#xD;
          -  PHASE 1: Know how to use TXT&#xD;
&#xD;
          -  PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase&#xD;
&#xD;
          -  PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase&#xD;
             inhibitors with anticipation of at least 6 month duration of use&#xD;
&#xD;
          -  PHASE 2: Able to read and understand English&#xD;
&#xD;
          -  PHASE 2: Able to provide informed consent&#xD;
&#xD;
          -  PHASE 2: Have a mobile device with TXT capability&#xD;
&#xD;
          -  PHASE 2: Willing to use a wireless pill bottle during study for 6 months&#xD;
&#xD;
          -  PHASE 2: Know or willing to learn how to use TXT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Cognitive impaired document in the electronic medical record (EMR)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kuang-Yi Wen, MD</last_name>
    <phone>215-503-4623</phone>
    <email>Kuang-Yi.Wen@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuang-Yi Wen, MD</last_name>
      <phone>215-503-4623</phone>
      <email>Kuang-Yi.Wen@Jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

